Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neutropenia 3Neoplasms 2Infections 2Hematologic Neoplasms 2Febrile Neutropenia 2Urinary Tract Infections 1Staphylococcal Infections 1Spasm 1Sleep Initiation and Maintenance Disorders 1Sepsis 1Seizures 1Schizophrenia, Treatment-Resistant 1Schizophrenia 1Retinitis 1Renal Insufficiency, Chronic 1Pulmonary Arterial Hypertension 1Pneumonia 1Pain 1Migraine Disorders 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Menorrhagia 1Meningitis, Bacterial 1Meningitis 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Intraabdominal Infections 1Influenza, Human 1Inflammation 1Hypokalemia 1Hypertension 1

Interventions

Oxaliplatin 270Bevacizumab 260Fluorouracil 249Irinotecan 240Leucovorin 218Capecitabine 196Cetuximab 161Colonoscopy 74Folfox protocol 70Panitumumab 64regorafenib 62Drug Therapy 52Radiotherapy 50HMPL-013 50Blood Specimen Collection 45trifluridine tipiracil drug combination 43pembrolizumab 41Surveys and Questionnaires 35Standard of Care 35Nivolumab 34Neoadjuvant Therapy 34Surgical Procedures, Operative 33Magnetic Resonance Spectroscopy 31IFL protocol 27Trifluridine 26Interviews as Topic 26Celecoxib 26XELOX 25Early Intervention, Educational 24Specimen Handling 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Colorectal Neoplasms × Vancomycin × Clear all
NCT04729322 2025-12-23

Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
15 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡